Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that new data from the Phase 3 MARIPOSA study will be presented at the 2025 European Lung Cancer Congress (ELCC).
The study shows that RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly improved median overall survival by more than one year compared to osimertinib in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.
Yusri Elsayed, M.D., Ph.D., Global Therapeutic Area Head, Oncology at Johnson & Johnson Innovative Medicine, said that the new data will transform treatment discussions and patient expectations. Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Lead, added that the chemotherapy-free regimen represents an innovative and life-extending option for patients.
Additional presentations will include data from the Phase 2 COCOON study evaluating a preventative dermatologic regimen, which met its primary endpoint and improved patient experience. The Phase 2 PALOMA-2 study, assessing the feasibility of switching to subcutaneous amivantamab, will also be highlighted.
Atossa Therapeutics secures new US patent for (Z)-endoxifen formulations
Akeso's Ebdarokimab approved in China for moderate-to-severe plaque psoriasis
Ymmunobio's YB-800 ADCs achieve proof of concept in preclinical in vitro and in vivo Tests
SparX to present Phase 1 clinical update during AACR 2025
Hoth Therapeutics secures Japanese patent for RNA-based therapy targeting KIT gene
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment